Form 4 for LYEL Lyell Immunopharma, Inc.
Accepted 2024-02-13 00:00:00 ET · period of report 2024-02-09 · accession 0001209191-24-003269 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-02-13 | 2024-02-09 | LYEL | Seely Lynn | Pres, CEO, Dir | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-09 | A | A | 200,000 | $0.00 | 200,000 | D | — | — |